DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing treatments for severe ischemic diseases. Its lead candidate, DM199, is a recombinant form of the human tissue kallikrein-1 protein currently in Phase 2/3 trials for acute ischemic stroke and Phase 2 trials for preeclampsia, cardio renal disease, and fetal growth restriction. The company also has a preclinical program, DM300, a recombinant human ulinastatin aimed at inflammatory diseases like acute pancreatitis. DiaMedica aims to improve outcomes for patients suffering from conditions involving insufficient blood flow and inflammation.

DiaMedica Therapeutics Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol DMAC. Its shares are traded in US dollars (USD). The company is headquartered in Minneapolis, Minnesota, United States, and operates primarily in the US market.

DiaMedica Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical stage biopharmaceutical company, it focuses on developing recombinant protein therapies for ischemic and inflammatory diseases. Biotechnology companies like DiaMedica use biological processes to create drugs, often targeting complex conditions such as stroke and preeclampsia.

DiaMedica Therapeutics Inc. is headquartered in Minneapolis, Minnesota, United States. The company was incorporated in 2000 and was formerly known as DiaMedica Inc. before rebranding to DiaMedica Therapeutics Inc. in December 2016. It operates as a clinical stage biopharmaceutical company, primarily serving the US market with its pipeline of therapies for severe ischemic diseases.